BrainsWay Ltd.
NASDAQ:BWAYMedical - Devices
+$0.05 today
- Market cap
- $342.42M
- Beta
- 0.15
- P/E (TTM)
- 61.7
- EPS (TTM)
- $0.23
Volume 0.12M
Average 0.15M
Returns on capital
BrainsWay Ltd. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
10.4%
avg -28.1%
ROIC
4.7%
avg -16.2%
ROA
6.8%
avg -13.9%
Analysis
ROE is currently the strongest return metric at 10.4% versus its period average of -28.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Hadar Levy | Chief Executive Officer | USD 687.98K | 53 | 62.50K | 0.16% |
Ido Marom | Chief Financial Officer | USD 430.8K | 50 | 17.50K | 0.04% |
Michael Cohen | Vice President of US Sales | USD 377.3K | — | — | — |
Colleen Hanlon | Vice President of Medical Affairs | USD 331.49K | 46 | 10.00K | 0.03% |
Gilead Moiseyev | Chief Technology Officer | USD 309.81K | 54 | — | — |
Yiftach Roth | Founder & Chief Scientific Officer | USD 108K | 55 | 1.08M | 2.75% |
Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director | USD 72.18K | 56 | 25.00K | 0.06% |
David Zacut | Co-Founder & Vice-Chairman | USD 42.97K | 73 | 25.00K | 0.06% |
Dor Hagai | Vice President of Operations | — | — | — | — |
Menachem C. Klein | Vice President, General Counsel & Corporate Secretary | — | — | — | — |
Naomi Rozenfeld | Chief Marketing Officer | — | 41 | 25.00K | 0.06% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
3
$0.00
Net Transaction Value
Neutral
Balanced transaction value
Most Active
Mitrany Rayten Michal Ety
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 15, 26Jun 15, 2026 | Moiseyev Gilad Direct | Sell | $0$0.00 |
| May 26, 26May 26, 2026 | Mitrany Rayten Michal Ety Direct | Sell | $0$0.00 |
| May 25, 26May 25, 2026 | Mitrany Rayten Michal Ety Direct | Sell | $0$0.00 |
Summary
Insiders reported 0 buys worth $0.00 and 3 sells worth $0.00 over the last 12 months. Reported purchase and sale values were balanced. Mitrany Rayten Michal Ety was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +13.8% (3yr)1 analysts |
| Revenue | N/A | N/A | +24.3% | +24.9% (3yr)2 analysts |
| Net Income | N/A | N/A | N/A | +13.6% (3yr)2 analysts |
| EBIT | N/A | N/A | N/A | +52.9% (3yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +24.3% over three years. Forward estimates point to EBIT at +52.9% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does BrainsWay Ltd. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about BWAY's management, answered from reported figures.
Who manages BWAY?
BrainsWay Ltd. (BWAY) lists 11 active executives. The top listed executive is David Zacut, Co-Founder & Vice-Chairman.
Are BWAY insiders buying or selling?
Recent insider activity shows net buying of $0.00.
Continue the stock analysis
Jump to another research area for this company.